Navigation Links
PET scan with [11C]erlotinib may provide noninvasive method to identify TKI-responsive lung tumors

A non-invasive PET imaging technique may identify lung cancers that respond best to tyrosine kinase inhibitors (TKIs), allowing doctors to better select patients for personalized therapy, according to research presented at the 14th World Conference on Lung Cancer in Amsterdam, hosted by the International Association for the Study of Lung Cancer (IASLC).

"As more and more therapeutic agents are becoming available for non-small cell lung cancer therapy, selecting the best drug for each individual patient becomes increasingly challenging," said principal investigator Dr. Idris Bahce, of VU University Medical Center in Amsterdam, the Netherlands. "Predictive markers may offer guidance in personalizing therapy."

One marker that predicts tumor response to TKIs is the activating mutation of the epidermal growth factor receptor (EGFR) gene of the tumor cells, Dr. Bahce said. But it's not easy to obtain adequate tumor tissue from the patient for DNA analysis to determine whether the mutation exists.

In the study, non-small cell lung cancer (NSCLC) patients underwent PET (positron emission tomography) scans using radiolabeled erlotinib, a TKI.

"We found that patients who had an activating EGFR mutation also had an increased tracer uptake and were more sensitive to treatment with erlotinib as compared to those who did not have this mutation," Dr. Bahce said. "This is an important finding, as it indicates that this new imaging PET technique may be a non-invasive predictive marker that identifies NSCLC patients who benefit from treatment with TKIs."

Ten NSCLC patients, five with wild-type EGFR and five with activating EGFR mutations -- determined by DNA sequencing on tumor tissue -- were included in the study. Each was scanned twice using a procedure that included a low-dose computed tomography (CT) scan, a 10 minute [15O]water dynamic PET scan and a one-hour [11C]erlotinib dynamic PET scan.

Tumor uptake of [11C]erlotinib was significantly higher in the mutated group (median uptake (VT) = 1.70; range 1.33-2.30) than in the wild-type group (median uptake (VT) = 1.18; range, 0.75-1.34; p = 0.03). This difference was not due to differences in tumor perfusion. Tracer [11C]erlotinib uptake correlated with tumor response to subsequent erlotinib treatment, as only high-uptake tumors responded to treatment.


Contact: Renee McGaw
International Association for the Study of Lung Cancer

Related medicine news :

1. New Website Provides Counselors with Instant Help for Troubled Kids
2. American Council on Exercise (ACE) Study Reveals Kettlebells Provide Powerful Workout in Short Amount of Time
3. Medical Transcription Services and EHR Provider MxSecure Launches New Enhanced Website with Goal of Improved Physician Productivity
4. Providence Service Corporation Relocates Corporate Headquarters to Downtown Tucson
5. Keenan Chief Strategy Officer Selected to Join Editorial Board of Payers & Providers
6. DavisPTnetwork Partners with the New York Physical Therapy Association to Provide Online Continuing Education
7. Rhode Island Settlement Reflects Homeowner Liability for Serving Alcohol to Those Under 21, Says Providence Lawyer Mark Gemma
8. Southridge LLC Provides Equity Capital Through Private Agreement with PuraMed Bioscience
9. MarquisNet Co-Location Agreement with MessageBroadcast Helps Message Delivery Provider Expand World-Class Network
10. Top Raleigh Dentist Robert Williamson Designated A Preferred Invisalign Provider
11. Save the Children Provides Songs with Lifesaving Health and Nutrition Advice to Haitian Radio Stations
Post Your Comments:
(Date:10/13/2015)... ... , ... Tempe Dental Care, a leading Tempe dentists’ office, celebrates offering gentle, ... for more than 5 years. A leading cause of emergency room visits, school ... is not timely. , Sedation dentistry provides an anxiety-free dental experience ...
(Date:10/13/2015)... ... ... Local Gold’s Gym franchise owner, Bryce Berry, received the Visionary of the ... and operates Gold's Gym Cheyenne in Cheyenne, Wyoming, received the award in ... A brand leader in global fitness, Gold’s Gyms are located worldwide. Every fitness center ...
(Date:10/13/2015)... (PRWEB) , ... October 13, 2015 , ... ... Dr. Bill Saye as the newest professional to introduce the latest development, ThermiVa® ... highly recognized as a leading professional in Obstetrics and Gynecology and a pioneer ...
(Date:10/13/2015)... ... 2015 , ... In an ongoing effort to provide the ... Texas, child development and pediatric therapy center, is working with TRICARE to emphasize ... options for receiving this kind of care for affected children. Because of concerns ...
(Date:10/13/2015)... ... October 13, 2015 , ... Just under three months ago, ... began a $1 promotion – effectively offering all of their services for just a ... the company was flooded with phone calls from interested buyers. As a genuine one-stop-shop ...
Breaking Medicine News(10 mins):
(Date:10/13/2015)... , Oct. 13, 2015 China Jo-Jo ... " China Jo-Jo "), a leading China-based retail, wholesale ... through its own online and retail pharmacies, announced preliminary ... official branded online pharmacy through , growing ... a record 25%. China Jo-Jo,s ...
(Date:10/13/2015)... Oct. 13, 2015  Asterias Biotherapeutics, Inc. (NYSE ... UK-based Cell Therapy Catapult to advance development of ... dendritic cell immunotherapy. Under the agreement, the Cell ... for AST-VAC2 to support advanced clinical trials and ... --> The Cell Therapy Catapult ...
(Date:10/12/2015)...  Former White House Spokesman, and Drug Czar Public Affair ... Committee, Robert Weiner , and Policy Analyst Daniel ... that this is now a potential bipartisan campaign and debate ... , Carly Fiorina to Rand Paul ... which they call "a shocker: 23 million need but do ...
Breaking Medicine Technology: